Treatment patterns of eosinophilic esophagitis in the biologic era—a real-world analysis
Rattachement africain : at, de, br. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Eosinophilic esophagitis is a chronic immune-mediated disease requiring a long-term maintenance treatment. The data on therapy patterns and treatment durability in the biologic era are scarce in a real-world setting. The aim of this project was to provide information on the treatment courses in a real-world setting over past 10 years. Data on demographics, concomitant atopic diseases and treatments were collected retrospectively at seven Austrian centres. The eligible subjects had to start their first therapy between January 2014 and February 2025. In total, 336 patients (30.1% female) were analyzed of whom 34.5% remained on the first line treatment. In a mean time of 7.6 months, a second line treatment was started. The most common first line treatment was swallowed topical corticosteroids (STCs) (54.2%), followed by proton pump inhibitors (22.3%) and food elimination diet (6.0%). In contrast to only a minority who continued on PPI therapy after starting it (21.3%), the majority of patients had ongoing STC treatment (51%). Forty-one (12.2%) patients received a treatment with dupilumab of whom only one as first line treatment (because of multiple type 2 inflammatory diseases) and the majority as second line treatment (57.5%). The reasons for dupilumab were non-response to STC (59%), followed by side effects (24%). 97.6% (40/41) of them remained on dupilumab until the last follow-up. Although most patients receive STC at the beginning, the majority need multiple treatment lines. Dupilumab is used in a tenth of patients due to refractoriness, side-effects or treatment of other type 2 inflammatory diseases.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Treatment patterns of eosinophilic esophagitis in the biologic era—a real-world analysis
- Date Crossref
- 12/05/2026
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Medical University of Vienna Department of Internal Medicine III pays non établi dans la noticeUniversité ou école supérieure
-
AGO Austria pays non établi dans la noticeOrganisation à but non lucratif
-
Klinikum Wels-Grieskirchen pays non établi dans la noticeÉtablissement de santé
-
Hospital of the Brothers of St. John of God pays non établi dans la noticeÉtablissement de santé
-
Immunomedics (Germany) pays non établi dans la noticeEntreprise
-
Barmherzige Schwestern Krankenhaus Wien pays non établi dans la noticeÉtablissement de santé
-
Ordensklinikum Linz Barmherzige Schwestern pays non établi dans la noticeÉtablissement de santé
-
Atitus Educação pays non établi dans la noticeUniversité ou école supérieure
-
Medical University of Graz Department of Internal Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Department of Gastroenterology and Hepatology pays non établi dans la noticeInstitution
-
Department of Internal Medicine I pays non établi dans la noticeInstitution
-
Gastromedics pays non établi dans la noticeInstitution
Department of Internal Medicine III — Medical University of Vienna, AGO Austria et Klinikum Wels-Grieskirchen, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.